Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment

Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment

Introduction: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract. Biologic drugs target specific molecules in the body’s immune system to control inflammation. Recent studies have suggested a potential link between their use and an increased risk of nephrolit...

Full description

Bibliographic Details
Main Authors: Zakaria Alameddine, Racha Abi Melhem, Reem Dimachkie, Hussein Rabah, Hamed Chehab, Michel El Khoury, Faris Qaqish, Dimitre Stefanov, Suzanne El-Sayegh
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Journal of Clinical Medicine
Subjects:
nephrolithiasis
inflammatory bowel disease
biologics
vedolizumab
urolithiasis
stone
Online Access:https://www.mdpi.com/2077-0383/12/19/6114

Internet

https://www.mdpi.com/2077-0383/12/19/6114

Similar Items